Naomi Eichenbaum - Erytech Pharma Director Relations
Insider
Naomi Eichenbaum is Director Relations of Erytech Pharma SA
| Phone | 33 4 78 74 44 38 |
| Web | https://www.erytech.com |
Erytech Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3014) % which means that it has lost $0.3014 on every $100 spent on assets. This is way below average. Erytech Pharma's management efficiency ratios could be used to measure how well Erytech Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Erytech Pharma SA currently holds 13.57 M in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Erytech Pharma SA has a current ratio of 2.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Erytech Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Christopher Garcia | Surrozen | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| Steven Martin | Armata Pharmaceuticals | 63 | |
| Nick Rigopoulos | XORTX Therapeutics | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| David MacDonald | XORTX Therapeutics | 61 | |
| Gerald Goodman | Nutriband | 77 | |
| Brian Varnum | Armata Pharmaceuticals | 64 | |
| Pascal Caisey | Genfit | 56 | |
| Timothy Dyer | Addex Therapeutics | 57 | |
| Roeland Nusse | Surrozen | 75 | |
| Alexandra MD | Avenue Therapeutics | 58 | |
| Elizabeth Nguyen | Surrozen | N/A | |
| Erin Butler | Armata Pharmaceuticals | N/A | |
| Roger MD | Addex Therapeutics | 68 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Duane BA | Armata Pharmaceuticals | 74 | |
| Pascal Prigent | Genfit | 57 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Robert Lutjens | Addex Therapeutics | 56 | |
| John CPA | Unicycive Therapeutics | 63 | |
Management Performance
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 |
Erytech Pharma SA Leadership Team
Elected by the shareholders, the Erytech Pharma's board of directors comprises two types of representatives: Erytech Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Erytech. The board's role is to monitor Erytech Pharma's management team and ensure that shareholders' interests are well served. Erytech Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Erytech Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gil BVBA, CEO Director | ||
| Iman MD, Chief Officer | ||
| Philip Lorenzi, Consultant Board | ||
| AnneCcile Fumey, HR Director | ||
| Brian Schwab, Chief Counsel | ||
| Naomi Eichenbaum, Director Relations | ||
| Eric Soyer, CFO, COO | ||
| Bridget Bax, Consultant Board | ||
| Jrme PharmD, Chief Operations | ||
| Pr MD, Consultant Board |
Erytech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Erytech Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Shares Owned By Institutions | 7.65 % | |||
| Number Of Shares Shorted | 17.79 K | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |